Serodiagnosis of pulmonary disease due to Mycobacterium avium complex proven by bronchial wash culture.

Affi liations: From the Department of Pharmacy (Drs Ogale and Sullivan), University of Washington; the Center for Management of Complex Chronic Care (Dr Lee), Edward Hines Jr VA Hospital; and the Center for Pharmacoeconomic Research, Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL. Dr Ogale is currently at Genentech, Inc. Financial nonfi nancial disclosures: The authors have reported to CHEST the following confl icts of interest: Dr Ogale is an employee of Genentech, Inc. Drs Lee and Sullivan have received funding for their contribution to the Burden of Obstructive Lung Disease (BOLD) Initiative, which has been funded in part by unrestricted educational grants to the Operations Center ( www . boldcopd . org ) from ALTANA, Aventis, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novartis, Pfi zer, Schering-Plough, Sepracor, and the University of Kentucky. Drs Lee and Sullivan have received past research grants from AstraZeneca, Boehringer Ingelheim, Pfi zer, Novartis, and Glaxo SmithKline. Dr Lee has participated in past advisory boards for AstraZeneca and Novartis. Correspondence to: Todd A. Lee, PharmD, PhD, Edward Hines Jr VA Hospital (151-H), 5000 S 5th Ave, Hines, IL 60141; e-mail: [email protected] © 2010 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( www . chestpubs . org site misc reprints . xhtml ). DOI: 10.1378/chest.10-0403